A detailed history of Comerica Securities,Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Comerica Securities,Inc. holds 1,549 shares of VRTX stock, worth $778,295. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,549
Previous 1,784 13.17%
Holding current value
$778,295
Previous $627,000 14.19%
% of portfolio
0.04%
Previous 0.04%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 26, 2023

SELL
$338.18 - $362.46 $79,472 - $85,178
-235 Reduced 13.17%
1,549 $538,000
Q2 2023

Aug 04, 2023

BUY
$314.42 - $351.91 $4,401 - $4,926
14 Added 0.79%
1,784 $627,000
Q1 2023

Apr 27, 2023

SELL
$283.23 - $323.1 $119,523 - $136,348
-422 Reduced 19.25%
1,770 $557,000
Q4 2022

Feb 10, 2023

SELL
$285.76 - $321.48 $25,432 - $28,611
-89 Reduced 3.9%
2,192 $633,000
Q3 2022

Nov 07, 2022

BUY
$273.83 - $305.53 $15,882 - $17,720
58 Added 2.61%
2,281 $660,000
Q2 2022

Jul 19, 2022

SELL
$234.96 - $292.55 $178,099 - $221,752
-758 Reduced 25.43%
2,223 $626,000
Q1 2022

Apr 28, 2022

SELL
$221.42 - $260.97 $65,540 - $77,247
-296 Reduced 9.03%
2,981 $778,000
Q4 2021

Feb 10, 2022

BUY
$177.01 - $223.45 $53,103 - $67,035
300 Added 10.08%
3,277 $720,000
Q3 2021

Nov 10, 2021

BUY
$181.39 - $202.99 $21,041 - $23,546
116 Added 4.05%
2,977 $540,000
Q2 2021

Aug 11, 2021

BUY
$187.49 - $221.1 $149,617 - $176,437
798 Added 38.68%
2,861 $577,000
Q1 2021

May 12, 2021

BUY
$207.02 - $241.31 $115,517 - $134,650
558 Added 37.08%
2,063 $443,000
Q4 2020

Feb 09, 2021

BUY
$207.01 - $276.09 $76,386 - $101,877
369 Added 32.48%
1,505 $356,000
Q3 2020

Nov 04, 2020

BUY
$255.65 - $303.1 $67,747 - $80,321
265 Added 30.42%
1,136 $309,000
Q2 2020

Jul 17, 2020

SELL
$225.48 - $295.8 $676 - $887
-3 Reduced 0.34%
871 $253,000
Q1 2020

Apr 16, 2020

BUY
$199.77 - $247.81 $174,598 - $216,585
874 New
874 $207,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Comerica Securities,Inc. Portfolio

Follow Comerica Securities,Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Securities,Inc., based on Form 13F filings with the SEC.

News

Stay updated on Comerica Securities,Inc. with notifications on news.